By Bill Berkrot(Reuters) - An experimental once-weekly medicine for type 2 diabetes developed by Eli Lilly and Co proved as effective in lowering blood sugar as Victoza from Danish drugmaker Novo Nordisk in an eagerly anticipated late stage study.The Lilly drug, dulaglutide, achieved the primary goal of the 599-patient study by demonstrating so-called non-inferiority to the highest approved dose of Victoza after 26 weeks, according to initial results released by the company on Tuesday.
Eli Lilly and Co (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals, Inc. received approval from the US Food and Drug Administration for their diabetes drug Glyxambi, a combination of two compounds, empagliflozin and linagliptin. The have been approved for adults with type II diabetes and function as an adjunct to diet and exercise to enhance glycemic control in patients for whom both the compounds are appropriate.
DepoMed Inc (NASDAQ:DEPO) has announced a $1.05 billion deal to acquire US license rights to painkiller Nucynta developed by Johnson & Johnson’s (NYSE:JNJ) Janssen Pharmaceuticals unit, as the company looks to establish itself as a specialty pharmaceutical focused on pain and neurology.
Mylan Inc. (MYL) has become a tough competitor in the biosimilar glargine race after announcing that it will begin Phase-III trials to show the non-inferiority of its experimental drug glargine when compared to Sanofi SA’s (SNY) diabetes drug Lantus.
Lantus generated revenue of $7.6 billion in fiscal year 2013. It and Mylan’s experimental drug will be used to treat type 2 diabetes mellitus patients.
Bristol-Myers Squibb Co (NYSE:BMY) and Merck & Co., Inc.’s (NYSE:MRK) respective cancer immunotherapies, Opdivo and Keytruda, showed promising results for the treatment of Hodgkin’s lymphoma in two separate studies, researchers announced Saturday.
As the flu rages through our population, many people will run to their doctors hoping for the miracle of modern medicine. When doctors see a patient with symptoms of the flu they often prescribe a drug known as Tamiflu, known generically as Oseltamivir. Tamiflu is a nuraminidase inhibitor, which means it blocks the actions of a protein that is essential for the flu virus to make copies of itself.
The Burrill Report submits: Pfizer (PFE) and Medivation (MDVN) said dimebon, their experimental drug to treat Alzheimer’s disease, failed in two late-stage clinical trials. Medivation’s stock, which had been trading at an all time high of $40.49 right before the news, tumbled nearly 70 percent to $13.04. In one trial, dimebon did not show statistical significance compared to placebo in measures of cognition and global function – the primary endpoints for the study.